Max Planck Institute Takes Delivery of Waters Synapt High Definition MS System

New Technology Expected to Enhance Neurodegenerative Disease Research

Programs



Jan 05, 2007, 00:00 ET from Waters Corporation

    MILFORD, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Waters Corporation
 (NYSE:   WAT) announced today that the world-renowned Max Planck Institute is
 enhancing its research on neurodegenerative diseases by adding a Waters(R)
 Synapt High Definition MS(TM) (HDMS) System to its complement of research
 technologies. The Institute's Department of Cellular Biochemistry recently
 took delivery of its Synapt(TM) HDMS System to study the role of proteins
 in causing brain-wasting diseases including Huntington's Disease.
     "Our initial impression of the Synapt HDMS system was of a very
 powerful two-dimensional separation device. We wanted a system that could
 measure large intact protein complexes with high accuracy. The ability to
 additionally separate species by ion mobility greatly enhances the appeal
 of this system," commented Prof. Ulrich Hartl, Director and Principal
 Investigator, Dr. Manajit Hayer-Hartl.
     Dr. Hayer-Hartl's research focuses on the understanding of the
 mechanisms by which molecular chaperones mediate protein folding and
 inhibit misfolding in neurodegenerative diseases. The Synapt System will
 analyze the large protein complexes, and their subunit composition, that
 are involved in such diseases. Prof. Hartl and Dr. Hayer-Hartl are looking
 to the Synapt System to give them greater insight into protein folding,
 assembly, and aggregation pathways by being able to resolve, identify and
 characterize intermediates based on differences in conformation, something
 that is nearly impossible to do with current technology.
     "We will follow folding and/or aggregation pathways in the presence or
 absence of chaperone systems in combination with hydrogen/deuterium
 exchange technology. The Synapt System's Triwave technology for separating
 ions by their mobility will allow us to characterize our proteins of
 interest in greater detail than any other mass spectrometry system
 currently available," Dr. Hayer-Hartl explained.
     Waters introduced the Synapt HDMS System at the American Society of
 Mass Spectrometry annual meeting in Seattle in June of 2006. It is the
 first commercially-available mass spectrometer to combine high-efficiency,
 ion mobility-based measurements and separations with a high-performance
 orthogonal acceleration time-of-flight mass spectrometer.
     About the Max Planck Institute
     The world-renowned Max Planck Institute of Biochemistry in Martinsried
 is one of the largest biomedical research institutes in Germany. It has 10
 departments focusing on aspects of biochemistry, biophysics, structural
 biology and cell biology.
     About Waters Corporation (www.waters.com)
     Waters Corporation holds worldwide leading positions in three
 complementary analytical technologies -- liquid chromatography, mass
 spectrometry and thermal analysis. These markets account for approximately
 $5.0 billion of the overall $20 - $25 billion analytical instrument market.
     Waters, Synapt, and High Definition MS are trademarks of Waters
 Corporation.
      Contact:
      Brian J. Murphy
      Corporate Communications
      +1 508-482-2614
      brian_j_murphy@waters.com
 
 

SOURCE Waters Corporation
    MILFORD, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Waters Corporation
 (NYSE:   WAT) announced today that the world-renowned Max Planck Institute is
 enhancing its research on neurodegenerative diseases by adding a Waters(R)
 Synapt High Definition MS(TM) (HDMS) System to its complement of research
 technologies. The Institute's Department of Cellular Biochemistry recently
 took delivery of its Synapt(TM) HDMS System to study the role of proteins
 in causing brain-wasting diseases including Huntington's Disease.
     "Our initial impression of the Synapt HDMS system was of a very
 powerful two-dimensional separation device. We wanted a system that could
 measure large intact protein complexes with high accuracy. The ability to
 additionally separate species by ion mobility greatly enhances the appeal
 of this system," commented Prof. Ulrich Hartl, Director and Principal
 Investigator, Dr. Manajit Hayer-Hartl.
     Dr. Hayer-Hartl's research focuses on the understanding of the
 mechanisms by which molecular chaperones mediate protein folding and
 inhibit misfolding in neurodegenerative diseases. The Synapt System will
 analyze the large protein complexes, and their subunit composition, that
 are involved in such diseases. Prof. Hartl and Dr. Hayer-Hartl are looking
 to the Synapt System to give them greater insight into protein folding,
 assembly, and aggregation pathways by being able to resolve, identify and
 characterize intermediates based on differences in conformation, something
 that is nearly impossible to do with current technology.
     "We will follow folding and/or aggregation pathways in the presence or
 absence of chaperone systems in combination with hydrogen/deuterium
 exchange technology. The Synapt System's Triwave technology for separating
 ions by their mobility will allow us to characterize our proteins of
 interest in greater detail than any other mass spectrometry system
 currently available," Dr. Hayer-Hartl explained.
     Waters introduced the Synapt HDMS System at the American Society of
 Mass Spectrometry annual meeting in Seattle in June of 2006. It is the
 first commercially-available mass spectrometer to combine high-efficiency,
 ion mobility-based measurements and separations with a high-performance
 orthogonal acceleration time-of-flight mass spectrometer.
     About the Max Planck Institute
     The world-renowned Max Planck Institute of Biochemistry in Martinsried
 is one of the largest biomedical research institutes in Germany. It has 10
 departments focusing on aspects of biochemistry, biophysics, structural
 biology and cell biology.
     About Waters Corporation (www.waters.com)
     Waters Corporation holds worldwide leading positions in three
 complementary analytical technologies -- liquid chromatography, mass
 spectrometry and thermal analysis. These markets account for approximately
 $5.0 billion of the overall $20 - $25 billion analytical instrument market.
     Waters, Synapt, and High Definition MS are trademarks of Waters
 Corporation.
      Contact:
      Brian J. Murphy
      Corporate Communications
      +1 508-482-2614
      brian_j_murphy@waters.com
 
 SOURCE Waters Corporation